Success Metrics

Clinical Success Rate
57.1%

Based on 4 completed trials

Completion Rate
57%(4/7)
Active Trials
0(0%)
Results Posted
75%(3 trials)
Terminated
3(38%)

Phase Distribution

Ph phase_4
2
25%
Ph not_applicable
3
38%
Ph phase_2
1
13%
Ph phase_3
1
13%

Phase Distribution

0

Early Stage

1

Mid Stage

3

Late Stage

Phase Distribution7 total trials
Phase 2Efficacy & side effects
1(14.3%)
Phase 3Large-scale testing
1(14.3%)
Phase 4Post-market surveillance
2(28.6%)
N/ANon-phased studies
3(42.9%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

50.0%

4 of 8 finished

Non-Completion Rate

50.0%

4 ended early

Currently Active

0

trials recruiting

Total Trials

8

all time

Status Distribution
Completed(4)
Terminated(4)

Detailed Status

Completed4
Terminated3
Withdrawn1

Development Timeline

Analytics

Development Status

Total Trials
8
Active
0
Success Rate
57.1%
Most Advanced
Phase 4

Trials by Phase

Phase 21 (14.3%)
Phase 31 (14.3%)
Phase 42 (28.6%)
N/A3 (42.9%)

Trials by Status

withdrawn113%
completed450%
terminated338%

Recent Activity

Clinical Trials (8)

Drug Details

Intervention Type
PROCEDURE
Total Trials
8